Tekla Capital Management LLC Vertex Pharmaceuticals Inc Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Tekla Capital Management LLC holds 318,043 shares of VRTX stock, worth $150 Million. This represents 4.43% of its overall portfolio holdings.

Number of Shares

318,043

Previous 330,343 3.72%

Holding current value

$150 Million

Previous $104 Million 7.53%

% of portfolio

4.43%

Previous 3.99%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $3.87 Million - $4.33 Million	-12,300 Reduced 3.72%	318,043 $112 Million
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $4.84 Million - $5.45 Million	16,940 Added 5.41%	330,343 $95.4 Million
Q3 2022 Nov 01, 2022	SELL	$273.83 - $305.53 $13.1 Million - $14.6 Million	-47,828 Reduced 13.24%	313,403 $90.7 Million
Q2 2022 Jul 29, 2022	BUY	$234.96 - $292.55 $12.3 Million - $15.3 Million	52,347 Added 16.95%	361,231 $102 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $7.94 Million - $9.35 Million	35,838 Added 13.13%	308,884 $80.6 Million

Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $22.2 Million - $24.8 Million	-122,242 Reduced 30.92%	273,046 $49.5 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $18.6 Million - $21.7 Million	89,978 Added 29.47%	395,288 $84.9 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $19.9 Million - $26.5 Million	-96,050 Reduced 23.93%	305,310 $72.2 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $19.4 Million - $23 Million	-75,970 Reduced 15.92%	401,360 $109 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $1.89 Million - $2.48 Million	-8,400 Reduced 1.73%	477,330 $139 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $1.61 Million - $2 Million	-8,059 Reduced 1.63%	485,730 $116 Million
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $1.09 Million - $1.47 Million	6,555 Added 1.35%	493,789 $108 Million
Q3 2019 Nov 13, 2019	SELL	$166.23 - $187.09 $415,575 - $467,725	-2,500 Reduced 0.51%	487,234 $82.5 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $7.58 Million - $8.76 Million	46,022 Added 10.37%	489,734 $89.8 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $2.86 Million - $3.4 Million	17,464 Added 4.1%	443,712 $81.6 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $2.74 Million - $3.46 Million	18,013 Added 4.41%	426,248 $70.6 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $29.1 Million - $33.4 Million	-173,287 Reduced 29.8%	408,235 $78.7 Million
Q2 2018 Aug 13, 2018	SELL	$145.72 - $169.96 $4.74 Million - $5.53 Million	-32,562 Reduced 5.3%	581,522 $98.8 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $4.5 Million - $5.26 Million	-29,678 Reduced 4.61%	614,084 $100 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $12 Million - $13.6 Million	-87,361 Reduced 11.95%	643,762 $96.5 Million
Q3 2017 Nov 13, 2017	SELL	$148.13 - $162.24 $9.91 Million - $10.9 Million	-66,930 Reduced 8.39%	731,123 $111 Million
Q2 2017 Aug 14, 2017	BUY	N/A	798,053	798,053 $103 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Vertex Pharmaceuticals Inc Transaction History